Carbon monoxide-induced parkinsonism

Summary

Carbon monoxide-induced parkinsonism (MONDO:0017639) is a disease and 2 clinical trials. Top therapeutic interventions include sodium chloride. A subtype of parkinsonian disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Phenotypes (HPO): 9
• Clinical trials: 2

Clinical features

Signs & symptoms

Clinical features (HPO)

9 HPO clinical features (Orphanet curated; top 9 by frequency):

HPO ID	Term	Frequency
HP:0000708	Atypical behavior	Very frequent (80-99%)
HP:0002354	Memory impairment	Very frequent (80-99%)
HP:0002518	Abnormal periventricular white matter morphology	Very frequent (80-99%)
HP:0012706	Elevated brain choline level by MRS	Very frequent (80-99%)
HP:0012708	Reduced brain N-acetyl aspartate level by MRS	Very frequent (80-99%)
HP:0002063	Rigidity	Frequent (30-79%)
HP:0002067	Bradykinesia	Frequent (30-79%)
HP:0002817	Abnormality of the upper limb	Frequent (30-79%)
HP:0004673	Decreased facial expression	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	carbon monoxide-induced parkinsonism
Mondo ID	MONDO:0017639
Orphanet	306686
SNOMED CT	230293003
UMLS	C0393565
MedGen	581450
GARD	0021265
Is cancer (heuristic)	no

Also known as: CO-induced parkinsonism

Disease family

This is a subtype of parkinsonian disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › basal ganglia disorder › parkinsonian disorder › carbon monoxide-induced parkinsonism

Related subtypes (20): postencephalitic Parkinson disease, Parkinson disease, dystonia 12, Perry syndrome, X-linked parkinsonism-spasticity syndrome, early-onset parkinsonism-intellectual disability syndrome, X-linked dystonia-parkinsonism, autosomal dominant striatal neurodegeneration type 1, dystonia 16, parkinsonism-dystonia, infantile, cirrhosis - dystonia - polycythemia - hypermanganesemia syndrome, hemiparkinsonism-hemiatrophy syndrome, cyanide-induced parkinsonism, atypical juvenile parkinsonism, primary progressive freezing gait, encephalitis lethargica, parkinsonism with dementia of Guadeloupe, multiple system atrophy, parkinsonian type, parkinsonism with polyneuropathy, vascular parkinsonism

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02138864	PHASE3	UNKNOWN	Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication
NCT06574048	PHASE1/PHASE2	NOT_YET_RECRUITING	Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SODIUM CHLORIDE	4	1